Melinta Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2018. For the quarter, the company reported total revenue of $14,841,000 compared to $22,463,000 a year ago. Loss from operations was $43,598,000 compared to income of $1,573,000 a year ago. Net loss was $29,432,000 compared to $74,000 a year ago. Net loss available to common shareholders was $29,432,000 compared to $5,794,000 a year ago. Basic and diluted net loss per share was $0.95 compared to $208.16 a year ago. Net cash used in operating activities was $51,420,000 compared to net cash provided by operating activities of $3,565,000 a year ago. Purchases of property, plant and equipment were $504,000 compared to $109,000 a year ago. LBITDA was $14,641,000 compared to EBITDA of $1,657,000 a year ago. Adjusted LBITDA was $31,575,000 compared to adjusted EBITDA of $2,284,000 a year ago. Net loss per share is impacted by changes in share count as a result of the Cempra merger and financing related to the acquisition of the infectious disease business from The Medicines Company.

For the year, the company expected strong growth and expect net product sales for these products to be combined in the range of $36 million to $40 million for the full year 2018.